Company: CERO
Filing Date: 2025-06-16
Form Type: 424B3
Source: 0001213900-25-054769
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-16
Form: 424B3
Chunk 5
---
 incorporated by reference therein. The risks described in the Company’s filings with the Securities and
Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors,
nor can the Company assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors
may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not
guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking
statements made by the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements.
The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. 
 3.1         
 99.1        |     | Description                                                                                                                  
 Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of CERo Therapeutics Holdings, Inc. 
 Press release, dated June 11, 2025.                                                                                          |
|:------------|:----|:-----------------------------------------------------------------------------------------------------------------------------|
| 104         |     | Cover Page Interactive Data File (Embedded within the Inline XBRL Document).                                                 |

<div align='center'>2

SIGNATURES</div>

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

| Date: June 11, 2025 | CERO THERAPEUTICS HOLDINGS, INC. |                         |
|:--------------------|:---------------------------------|:------------------------|
|                     | By:                              | /s/ Chris Ehrlich       |
|                     | Name:                            | Chris Ehrlich           |
|                     | Title:                           | Chief Executive Officer |

<div align='center'>3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2025

CERO